TPST Tempest Therapeutics, Inc.

CIK 0001544227 24 ready 8-Ks latest May 22, 2026 21:28 UTC RSS · JSON

Ready 8-Ks 24

Latest filing May 22, 2026 21:28 UTC

Top materiality 0.95

Event mix other_material ×12 · earnings ×6 · regulatory ×2

Sentiment 3 pos · 5 neg · 16 neu

Latest earnings reported 2025-Q3

Executive change recent →

Recent 8-K filings for TPST

Highest-materiality recent filing

Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing

Feb 06, 2026 23:59 UTC M&A materiality 0.95 neutral item 1.01 item 2.01 item 3.02 item 5.01 item 5.02 item 9.01

Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.
Erigen owns 61.3% of outstanding shares (13.48M total); its members Angel and Lotus Capital to own ~35.9% and 25.5%.

Read filing →

May 22, 2026 21:28 UTC regulatory materiality 0.90 negative item 3.01 item 5.02

Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign

Stockholders' equity of $822k vs Nasdaq's $2.5M minimum; 45 days to submit compliance plan by July 6, 2026.
May 22, 2026 21:05 UTC leadership materiality 0.40 negative item 5.02

Three directors resign from Tempest Therapeutics board effective May 22, 2026

Stephen Brady, Michael Raab, and Christine Pellizzari resigned from the Tempest board on May 22, 2026.
May 14, 2026 20:28 UTC earnings materiality 0.50 neutral item 2.02 item 9.01

Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials

Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.
May 06, 2026 23:59 UTC other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003

100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.
Mar 30, 2026 23:59 UTC earnings materiality 0.70 neutral item 2.02 item 9.01

Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition

Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.
Mar 23, 2026 23:59 UTC other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01

Tempest Therapeutics raises ~$2M in private placement of stock and warrants

Raised ~$2M gross from private placement of 462,964 shares + pre-funded warrants at $2.16 per unit.
Feb 25, 2026 23:59 UTC other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026

100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.
Feb 11, 2026 23:59 UTC other material materiality 0.20 neutral item 7.01 item 9.01

Tempest Therapeutics files updated corporate presentation; no specific new data disclosed in filing.

Company posted February 2026 investor presentation on its website.
Feb 06, 2026 23:59 UTC M&A materiality 0.95 neutral item 1.01 item 2.01 item 3.02 item 5.01 item 5.02 item 9.01

Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing

Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.
Jan 28, 2026 23:59 UTC other material materiality 0.50 neutral item 3.03 item 5.02 item 5.07

Tempest shareholders approve share issuance for asset purchase and extend rights plan

Approved issuance of 8,268,495 common shares for Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc.
Jan 09, 2026 23:59 UTC other material materiality 0.35 neutral item 3.01

Tempest Therapeutics gets Nasdaq notice for missing annual meeting; meeting set for Jan 27, 2026

Received Nasdaq deficiency letter on Jan 8, 2026 for failing to hold annual meeting within 12 months of fiscal year end Dec 31, 2024.
Nov 26, 2025 23:59 UTC other material materiality 0.70 neutral item 3.02 item 8.01 item 9.01

Tempest raises $4.25M upfront in registered direct offering; warrants add up to $4.1M

1,172,414 shares (or equivalents) sold at $3.625/share in registered direct offering for ~$4.25M gross.
Nov 19, 2025 23:59 UTC M&A materiality 0.85 neutral item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Tempest Therapeutics to acquire four CAR T assets in all-stock deal; CEO change, warrants issued

Acquires ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies for 8,268,495 shares of TPST common stock.
Nov 05, 2025 23:59 UTC earnings materiality 0.70 negative item 2.02 item 9.01

Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process

Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.
Aug 11, 2025 23:59 UTC earnings materiality 0.60 neutral item 2.02 item 9.01

Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China

Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.
Jun 12, 2025 23:59 UTC other material materiality 0.60 neutral item 1.01 item 7.01 item 8.01 item 9.01

Tempest Therapeutics raises ~$4.6M gross in registered direct offering of stock and prefunded warrants

Issued 405,000 shares at $6.25 each and prefunded warrants for 334,000 shares at $6.249 each.
Jun 11, 2025 23:59 UTC other material materiality 0.20 neutral item 8.01

Tempest Therapeutics suspends ATM prospectus; Sales Agreement remains in effect

Delivered notice to Jefferies to terminate ATM prospectus dated Feb 6, 2025.
Jun 06, 2025 23:59 UTC leadership materiality 0.75 negative item 5.02

Tempest Therapeutics transitions CEO, CMO, and CFO to consultants with equity acceleration

CEO Stephen Brady, CMO Samuel Whiting, CFO Nicholas Maestas transitioned to consulting agreements effective June 5, 2025.
May 13, 2025 23:59 UTC earnings materiality 0.65 neutral item 2.02 item 9.01

Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives

Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.
Apr 28, 2025 23:59 UTC regulatory materiality 0.65 positive item 8.01

Tempest Therapeutics regains Nasdaq minimum bid price compliance

Received Nasdaq notice on April 24, 2025 confirming compliance with Listing Rule 5550(a)(2).
Apr 18, 2025 23:59 UTC other material materiality 0.80 negative item 2.05

Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review

Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.
Apr 09, 2025 23:59 UTC other material materiality 0.80 neutral item 1.02 item 7.01 item 9.01

Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee

Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.
Apr 07, 2025 23:59 UTC other material materiality 0.65 neutral item 3.03 item 9.01

Tempest Therapeutics announces 1-for-13 reverse stock split effective April 8, 2025

Reverse stock split at 1:13 ratio, effective 5:00 p.m. ET on April 8, 2025.
Mar 27, 2025 23:59 UTC earnings materiality 0.65 neutral item 2.02 item 9.01

Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations

Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.